4D Molecular Therapeutics/$FDMT
1D1W1MYTD1Y5YMAX
Capital at risk
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
- Ticker
- $FDMT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 196
- Headquarters
- EmeryVille, United States
FDMT Metrics
BasicAdvanced
$799M
-
-$2.77
2.73
-
Price and volume
Market cap
$799M
Beta
2.73
52-week high
$16.93
52-week low
$6.96
Average daily volume
1.1M
Financial strength
Current ratio
8.033
Quick ratio
7.676
Long term debt to equity
0.083
Total debt to equity
0.096
Profitability
EBITDA (TTM)
-188.89
Gross margin (TTM)
-157.70%
Net profit margin (TTM)
-194.74%
Operating margin (TTM)
-210.76%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-25.09%
Return on equity (TTM)
-43.25%
Valuation
Price to revenue (TTM)
10.16
Price to book
1.96
Price to tangible book (TTM)
1.96
Price to free cash flow (TTM)
-5.993
Free cash flow yield (TTM)
-16.69%
Free cash flow per share (TTM)
-2.414
Growth
Revenue change (TTM)
278,712.12%
Earnings per share change (TTM)
-21.20%
3-year revenue growth (CAGR)
242.75%
3-year earnings per share growth (CAGR)
-5.35%
What the Analysts think about FDMT
Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.
Analyst projections of the future price of 4D Molecular Therapeutics stock.
Bulls say / Bears say
Two-year PRISM data showed maintained vision and retinal anatomy after one 4D-150 injection, with a 78% reduction in supplemental injections overall and 87% in recently diagnosed patients. No new intraocular inflammation was reported during follow-up beyond the first 28 weeks. (4D Molecular Therapeutics, Ophthalmology Times)
FDMT reported $430.6 million in cash, cash equivalents and marketable securities at the end of June and expects its current plan, including Otsuka payments, to be funded into at least the second half of 2028. A Hercules facility of up to $200 million, initially drawing $20 million, adds further funding flexibility without an immediate equity issue. (BioSpace, 4D Molecular Therapeutics)
The strongest efficacy evidence is still a small Phase 2b study, and its injection-burden comparison used projected aflibercept treatment rather than a randomised head-to-head control. The decisive Phase 3 tests remain capable of disproving the early signal. (Ophthalmology Times, 4D Molecular Therapeutics)
FDMT has no approved product or product sales, while its second-quarter net loss reached $72.9 million and research and development spending was $68.3 million. Continued losses mean shareholders may eventually face further financing or dilution before revenue arrives. (4D Molecular Therapeutics, Stock Titan)
The investment case is concentrated in two 4D-150 wet AMD readouts due in 2027, while the company is also adding a DME Phase 3 programme. That creates a long wait and meaningful execution risk: a delay, safety issue or weak result in either pivotal programme could materially reset expectations. (BioSpace, 4D Molecular Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
FDMT Financial Performance
Revenues and expenses
FDMT Earnings Performance
Company profitability
Upcoming events
No upcoming events
FDMT News
AllArticlesVideos
Funds containing FDMT
AllUSDGBPEUR
Fund name | Fund size | $FDMT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.